Executive Master | MedCHEM

Drug Development &
Clinical Pharmacology

MedCHEM

Modelling the path from molecule to innovative medicine.

An advanced program to navigate the entire drug lifecycle.

12
Months
60
ECTS Credits
7
Core Modules
2
Specialization Tracks
Scroll
Overview

Bridging molecular science and clinical development

The Executive Master in Drug Development & Clinical Pharmacology is an advanced, multidisciplinary program designed by Humanitas University to train highly qualified professionals capable of navigating the entire drug lifecycle with a strong focus on scientific research, novel biotechnologies and translational development.

The Program provides an integrated view of drug discovery and development, spanning from unmet medical needs and molecular target identification to clinical development, regulatory approval and post-marketing surveillance.

A distinctive feature is the systematic integration of in-silico modelling and simulation with experimental pharmacology, pharmaceutical sciences and clinical pharmacology.

The Master is conceived to bridge the gap between molecular science, preclinical and clinical development, equipping participants with the conceptual frameworks and practical tools required to operate effectively in academic research, pharmaceutical and biotechnology industries, and regulatory-driven environments.

Start Your Application
Why MedCHEM?

From Molecule to Innovative Medicine

The Executive Master in Drug Development & Clinical Pharmacology aims to equip participants with advanced scientific and methodological competencies to understand, design, and manage the entire drug development process, from early discovery to clinical application and post-marketing evaluation.

End-to-End Drug Lifecycle

From target identification and molecular design through clinical trials, regulatory approval, and post-marketing surveillance.

Computational Meets Experimental

Systematic integration of in-silico modelling with experimental and clinical pharmacology, reflecting current drug development standards.

Innovative Therapeutics

Including biologics, RNA-based drugs, advanced delivery systems, and cutting-edge drug discovery technologies.

Study Plan

Study Plan

The Master is structured over 12 months (60 ECTS) and delivered in a blended format, combining live online sessions with intensive on-campus weeks dedicated to practical and interactive activities.

The Program develops expertise in model-informed drug development, computational simulations, pharmacokinetics and pharmacodynamics, and innovative therapeutic technologies, including biologics and RNA-based medicines. Graduates will be prepared to contribute to multidisciplinary R&D teams, apply quantitative and translational approaches to optimize drug efficacy and safety, and operate effectively across academic, industrial, and regulatory environments involved in the development of innovative medicines.

Core Modules
1
In-Silico Discovery Research
Molecular simulations, computational studies to drug design, AI in computational biology and drug discovery (with real life cases and examples).
2
Pharmaceutical Chemistry and Biotechnologies
Medicinal chemistry for the discovery and manufacturing of small molecules, discovery and production of biologic drugs.
3
Biopharmaceutics and Drug Delivery
Pre-formulations and formulation of biopharmaceutics, consolidated and novel drug delivery systems, RNA, oligonucleotide drugs and vaccines.
4
Experimental Pharmacology
In vitro and in vivo pharmacological studies, pharmacokinetics and pharmacodynamics, mechanism of action analysis, receptor binding, and toxicological assessment across different levels of complexity.
5
Clinical Development
First-in-human studies, clinical trial design (Phases I–IV), clinical modelling and simulation, regulatory pathways, drug dossier preparation, marketing authorization, generics and biosimilars.
6
Clinical Pharmacology and Modelling
Pharmacokinetics and pharmacodynamics, drug–drug interactions, special populations, therapeutic drug monitoring, model-informed precision dosing, machine-learning models for the prediction of drug exposure, and pharmacogenetics.
7
Pharmacovigilance and Post-Marketing Analytics
Signal detection, risk management, real-world data and evidence, post-marketing surveillance, regulatory compliance, safety reporting and environmental toxicology.
Specialization Track (2 options)
A
Quantification of drug and biomarkers in biological matrices for systemic and local PK
Development and validation of bioanalytical methods for the quantification of xenobiotic in different biological matrices for clinical pharmacology studies (practical examples and applications).
B
Development of pharmacokinetic population modelling and predictive models
A hands-on track focused on building population pharmacokinetic models and predictive tools to optimize drug development and individualized therapy.
Medical Chemistry at Work — Project Work & Dissertation

The final applied project is developed in collaboration with industry, academia or research institutes. Students work on real-world drug development challenges under academic and/or industrial supervision.

Didactic Structure and Organization

The didactic organization includes:

  • Core modules shared by all participants, providing a common scientific and methodological foundation
  • A strong emphasis on integrated learning, connecting computational, experimental and clinical perspectives
  • Hands-on components, to be delivered within two different on campus specialization tracks
  • A final project work carried out under academic and/or industrial supervision

This format allows working professionals to combine executive education with ongoing professional commitments, exploring networking opportunities and career-advancing experiences.

Faculty

Faculty & Learning Ecosystem

The Master is delivered by a multidisciplinary Faculty composed of academic experts from Humanitas University and partner institutions, alongside professionals from the pharmaceutical and biotechnology sectors.

The learning ecosystem is enriched by:

  • Interaction with industry and research professionals
  • Exposure to real-world case studies and development scenarios
  • A network of academic, clinical and industrial partners supporting teaching activities and final projects

Scientific Coordination

Prof. Dario Cattaneo
Director
Associate Professor of Pharmacology
Clinical Pharmacologist at Humanitas Hospital

Prof. Maurizio D'Incalci
Co-Director
Full Professor NT of Pharmacology, Humanitas University
Head of the Anti-Cancer Pharmacology Laboratory, Humanitas Research Hospital

Prof. Michela Matteoli
Co-Director
Full Professor of Pharmacology and Vice-Rector for Research, Humanitas University
PhD MECM Coordinator

Skills & Career

Built for future drug developers

The program provides a strong foundation for careers at the interface between science, development and clinical application of medicines.

Who Should Apply

Graduates in Medicine, Pharmacy, Chemistry, Biotechnology, Biomedical and Life Sciences, and related scientific disciplines.

From Molecule to Medicine

Bridge the gap between molecular science, preclinical and clinical development with practical tools and conceptual frameworks.

Career Advancement

High-impact roles at the interface between science, development and clinical application of medicines.

Who should apply?

The Master is designed for graduates in:

  • Medicine
  • Pharmacy
  • Chemistry
  • Biotechnology
  • Biomedical and Life Sciences
  • Related scientific disciplines

It is particularly suited for early-career scientists and clinicians aiming to develop advanced expertise in drug development and clinical pharmacology, as well as for professionals seeking to reposition their careers toward translational research and R&D-oriented roles.

Which career paths may I pursue after graduation?

Graduates will acquire competencies enabling them to pursue high-impact roles such as:

  • Preclinical and clinical drug developer
  • Clinical pharmacologist
  • Drug modelling scientist or computational chemist
  • Pharmacovigilance and drug safety analyst
  • Formulation scientist
  • Academic or translational research scientist
The program provides a strong foundation for careers at the interface between science, development and clinical application of medicines.
Admissions

Admissions & Fees

The Executive Master admits a limited number of participants to ensure high-quality interaction and mentoring.

  • Duration: 12 months, starting in November 2026
  • Credits: 60 ECTS
  • Format: blended (live online teaching + on-campus immersive specialization, company based or company-assigned project work)
  • Tuition fees: €31.000
  • Fee waivers and scholarships: €21.000 for independent participants; €16.000 for selected participants with affiliations with Humanitas Hospitals
  • Admissions deadline: October 15th, 2026

The Master Direction may assign scholarships and further contributions based on specific merit requirements and external funding opportunities.

Key Dates

StartNovember 2026
EndNovember 2027
Duration12 months
LanguageEnglish
Deadline15th October 2026
Fee€31.000 (scholarships available)

Read the Call for Applications

Access to the Master is subject to an evaluation of the candidate's academic and professional titles. The Call for Applications is the official document all candidates must review before applying.

Download PDF
Get in Touch

Ready to shape the future of medicine?

Fill out the form and our team will contact you with detailed information about the program.